WO2008036967A3 - Novel heterocyclic compounds as lasy activators - Google Patents

Novel heterocyclic compounds as lasy activators Download PDF

Info

Publication number
WO2008036967A3
WO2008036967A3 PCT/US2007/079286 US2007079286W WO2008036967A3 WO 2008036967 A3 WO2008036967 A3 WO 2008036967A3 US 2007079286 W US2007079286 W US 2007079286W WO 2008036967 A3 WO2008036967 A3 WO 2008036967A3
Authority
WO
WIPO (PCT)
Prior art keywords
lasy
activators
heterocyclic compounds
novel heterocyclic
compound
Prior art date
Application number
PCT/US2007/079286
Other languages
French (fr)
Other versions
WO2008036967A2 (en
Inventor
Dumbala Srinivas Reddy
Indira Padmalayam
Debnath Bhuniya
Sivaram Pillarisetti
Ranjan Chakrabarti
Original Assignee
Reddy Us Therapeutics Inc
Dumbala Srinivas Reddy
Indira Padmalayam
Debnath Bhuniya
Sivaram Pillarisetti
Ranjan Chakrabarti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc, Dumbala Srinivas Reddy, Indira Padmalayam, Debnath Bhuniya, Sivaram Pillarisetti, Ranjan Chakrabarti filed Critical Reddy Us Therapeutics Inc
Publication of WO2008036967A2 publication Critical patent/WO2008036967A2/en
Publication of WO2008036967A3 publication Critical patent/WO2008036967A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a compound of formula (I), which is a free species and/or a pharmaceutically-acceptable salt or a stereoisomer of the compound of formula (I). Another aspect of the present invention provides the compound of the formula (I) as a Lipoic acid synthase (LASY) inducer
PCT/US2007/079286 2006-09-22 2007-09-24 Novel heterocyclic compounds as lasy activators WO2008036967A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84649906P 2006-09-22 2006-09-22
US60/846,499 2006-09-22

Publications (2)

Publication Number Publication Date
WO2008036967A2 WO2008036967A2 (en) 2008-03-27
WO2008036967A3 true WO2008036967A3 (en) 2008-09-18

Family

ID=39201359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079286 WO2008036967A2 (en) 2006-09-22 2007-09-24 Novel heterocyclic compounds as lasy activators

Country Status (1)

Country Link
WO (1) WO2008036967A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477279C2 (en) * 2007-06-05 2013-03-10 Санофи-Авентис Substituted benzoylaminoindan-2-carboxylic acids and related compounds
ES2647664T3 (en) 2011-01-04 2017-12-26 Novartis Ag Indole compounds or analogs thereof useful for the treatment of age-related macular degeneration (AMD)
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6273274B2 (en) 2012-06-28 2018-01-31 ノバルティス アーゲー Complement pathway modulators and uses thereof
JP6209605B2 (en) 2012-06-28 2017-10-04 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
ES2712190T3 (en) 2012-06-28 2019-05-09 Novartis Ag Modulators of the complement pathway and its uses
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6154897B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
KR20150036481A (en) 2012-07-12 2015-04-07 노파르티스 아게 Complement pathway modulators and uses thereof
BR112016022785B8 (en) 2014-04-04 2020-09-15 Iomet Pharma Ltd tryptophan-2,3-dioxigenase (tdo) and / or indoleamine-2,3-dioxigenase (acid) inhibitor compound, pharmaceutical composition, and use of tryptophan-2,3-dioxigenase (tdo) inhibitor and / or indoleamine-2,3dioxigenase (acid) or a pharmaceutically acceptable salt thereof for the manufacture of a medicinal product
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
GB201704476D0 (en) 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196111B2 (en) * 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196111B2 (en) * 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

Also Published As

Publication number Publication date
WO2008036967A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008036967A3 (en) Novel heterocyclic compounds as lasy activators
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
WO2007085895A3 (en) Fap inhibitors
WO2007105058A8 (en) Pyrazole compounds
WO2008083248A3 (en) Cyclopamine analogs
SG171593A1 (en) Inhibitors of c-fms kinase
RS53292B (en) Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2006052568A3 (en) Tgf-beta inhibitors
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2006133147A3 (en) Organic compounds
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2007003934A3 (en) 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
SG170729A1 (en) Processes and intermediates for preparing steric compounds
AU2008229327A8 (en) Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as beta-secretase inhibitors
WO2007008684A3 (en) Ligands of melanocortin receptors
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
ZA200800184B (en) Amino acid salts of rosiglitazone
WO2007062314A3 (en) Heterocyclic cetp inhibitors
WO2009040314A3 (en) Novel heteroaryl-substituted acetone derivatives, suitable for inhibiting phospholipase a2
WO2007081690A3 (en) Inhibitors of protein kinases
MX359363B (en) DIHYDROETORPHINES and THEIR PREPARATION.
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843055

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843055

Country of ref document: EP

Kind code of ref document: A2